股票 › PCRX
派西拉生物科学 PCRX
美股市值排名 #2962
$36.43 +$0.01 (+0.03%)
休市 · Nov 6, 10:00 pm ET · 最新盘后价 $36.43 0.00%
开盘$36.42
昨收$36.42
当日区间$36.42 – $36.45
成交量537.1K
市值$1.46B
市盈率（TTM）39.2
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$192.40M+6.2% YoY
营业利润$11.86M+29.9% YoY
净利润$4.65M+196.0% YoY
摊薄每股收益$0.12+209.1% YoY
自由现金流$56.12M+502.5% YoY
经营现金流$57.46M
营收，近8个季度
净利润，近8个季度
各季度摊薄每股收益
各季度自由现金流
年度营收
盈利能力与资产负债表
毛利率79.2%
营业利润率2.5%
净利率2.0%
净资产收益率2.0%
资产收益率1.1%
投入资本回报率1.1%
流动比率5.04
负债/资产比率46.0%
现金及投资$251.03M
总负债$401.82M
净现金（净负债）-$150.79M
自由现金流/营收24.1%
营收构成
2026/Q2 季度
按业务线
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 报告营业总收入 | $192.40M | $177.38M | $726.41M | $196.87M | $179.52M |
| 营业总收入 | $192.40M | $177.38M | $726.41M | $196.87M | $179.52M |
| 营业成本 | $44.16M | $36.41M | $149.75M | $40.30M | $34.28M |
| 毛利润 | $148.24M | $140.96M | $576.66M | $156.57M | $145.24M |
| 营业费用 | $136.37M | $136.34M | $557.47M | $167.50M | $132.09M |
| 销售及管理费用 | $91.81M | $93.94M | $368.76M | $101.61M | $91.80M |
| -销售及营销费用 | $52.12M | $58.17M | $226.62M | $61.61M | $58.47M |
| -管理费用 | $39.69M | $35.78M | $142.14M | $40.00M | $33.33M |
| 研发费用 | $30.24M | $28.07M | $117.31M | $37.45M | $25.97M |
| 折旧、摊销与折耗 | $14.32M | $14.32M | $57.29M | $14.32M | $14.32M |
| -折旧与摊销 | $14.32M | $14.32M | $57.29M | $14.32M | $14.32M |
| 营业利润 | $11.86M | $4.63M | $19.19M | -$10.92M | $13.15M |
| 非经营性利息净收入（支出） | -$1.68M | -$1.77M | $5.29M | -$1.60M | $4.26M |
| 非经营性利息收入 | $1.94M | $1.93M | $22.73M | $2.30M | $8.53M |
| 非经营性利息支出 | $3.10M | $3.18M | $14.61M | $3.37M | $3.65M |
| 其他财务成本合计 | $521,000.00 | $521,000.00 | $2.84M | $520,000.00 | $626,000.00 |
| 其他收入（支出） | -$7.63M | $2.14M | -$7.60M | $13.09M | -$7.88M |
| 特殊收益（费用） | -$7.59M | $2.28M | -$983,000.00 | $13.26M | -$7.77M |
| -减：重组及并购费用 | $1.66M | -$2.28M | – | – | $4.07M |
| -业务出售收益 | -$5.93M | – | – | – | – |
| 其他非经营性收入（支出） | -$34,000.00 | -$135,000.00 | -$6.62M | -$172,000.00 | -$110,000.00 |
| 税前利润 | $2.56M | $5.00M | $16.87M | $571,000.00 | $9.52M |
| 税费 | -$2.10M | $2.08M | $9.84M | -$1.07M | $4.09M |
| 净利润 | $4.65M | $2.92M | $7.03M | $1.64M | $5.43M |
| 持续经营利润 | $4.65M | $2.92M | $7.03M | $1.64M | $5.43M |
| 归属母公司净利润 | $4.65M | $2.92M | $7.03M | $1.64M | $5.43M |
| 归属普通股股东净利润 | $4.65M | $2.92M | $7.03M | $1.64M | $5.43M |
| 基本每股收益 | $0.12 | $0.07 | $0.16 | $0.04 | $0.12 |
| 摊薄每股收益 | $0.12 | $0.07 | $0.16 | $0.04 | $0.12 |
| 其他营业费用 | – | – | $14.11M | – | – |
| -减：资本性资产减值 | – | – | $0.00 | -$25.87M | $25.87M |
| -减：其他特殊支出 | – | – | $983,000.00 | $16.15M | -$22.17M |
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 总资产 | $1.24B | $1.21B | $1.26B | $1.26B | $1.30B |
| 流动资产合计 | $615.22M | $514.96M | $547.97M | $547.97M | $562.75M |
| 现金及现金等价物与短期投资 | $251.03M | $202.18M | $238.42M | $238.42M | $246.33M |
| -现金及现金等价物 | $205.88M | $144.31M | $158.55M | $158.55M | $147.59M |
| -短期投资 | $45.16M | $57.87M | $79.88M | $79.88M | $98.75M |
| 应收款 | $132.42M | $125.64M | $124.07M | $124.07M | $115.27M |
| -应收账款 | $132.42M | $125.64M | $124.07M | $124.07M | $115.27M |
| 存货 | $134.58M | $150.37M | $152.86M | $152.86M | $157.68M |
| 其他流动资产 | $29.85M | $36.78M | $32.62M | $32.62M | $43.47M |
| 非流动资产合计 | $628.76M | $693.57M | $716.94M | $716.94M | $734.83M |
| 固定资产净值 | $175.20M | $175.69M | $182.47M | $182.47M | $191.65M |
| -固定资产原值 | $326.08M | $320.40M | $320.17M | $320.17M | $324.32M |
| -累计折旧 | -$150.88M | -$144.71M | -$137.70M | -$137.70M | -$132.67M |
| 商誉及其他无形资产 | $305.13M | $373.00M | $388.31M | $388.31M | $402.71M |
| -商誉 | $19.64M | $19.77M | $20.21M | $20.21M | $20.32M |
| -其他无形资产 | $285.48M | $353.23M | $368.10M | $368.10M | $382.40M |
| 一年以上递延资产 | $124.60M | $122.12M | $123.85M | $123.85M | $120.19M |
| 其他非流动资产 | $23.84M | $22.77M | $22.31M | $22.31M | – |
| 负债合计 | $572.00M | $554.64M | $571.81M | $571.81M | $570.36M |
| 流动负债合计 | $122.01M | $108.79M | $120.59M | $120.59M | $107.08M |
| 应付款 | $17.51M | $14.01M | $15.15M | $15.15M | $17.69M |
| -应付账款 | $17.51M | $14.01M | $15.15M | $15.15M | $17.69M |
| 一年内应计费用 | $66.51M | $84.96M | $57.76M | $57.76M | $79.64M |
| 短期债务及融资租赁负债 | $10.30M | $9.82M | $9.84M | $9.84M | $9.75M |
| -一年内到期融资租赁负债 | $10.30M | $9.82M | $9.84M | $9.84M | $9.75M |
| 其他流动负债 | $705,000.00 | – | – | – | – |
| 非流动负债合计 | $449.99M | $445.85M | $451.22M | $451.22M | $463.29M |
| 长期债务及融资租赁负债 | $401.82M | $401.36M | $408.37M | $408.37M | $415.56M |
| -长期债务 | $363.12M | $367.66M | $372.19M | $372.19M | $376.72M |
| -长期融资租赁负债 | $38.70M | $33.71M | $36.18M | $36.18M | $38.84M |
| 一年以上递延负债 | $4.07M | $4.09M | $4.21M | $4.21M | $4.59M |
| 其他非流动负债 | $44.10M | $40.40M | $38.64M | $38.64M | $43.14M |
| 股东权益合计 | $671.98M | $653.89M | $693.11M | $693.11M | $727.21M |
| 股东权益 | $671.98M | $653.89M | $693.11M | $693.11M | $727.21M |
| 股本 | $49,000.00 | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 |
| -普通股 | $49,000.00 | $48,000.00 | $48,000.00 | $48,000.00 | $48,000.00 |
| -优先股 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 资本公积 | $1.09B | $1.07B | $1.06B | $1.06B | $1.05B |
| 留存收益 | -$191.75M | -$196.41M | -$199.32M | -$199.32M | -$200.96M |
| 减：库存股 | $227.01M | $227.01M | $176.57M | $176.57M | $125.54M |
| 不影响留存收益的损益 | $3.24M | $3.46M | $4.33M | $4.33M | $4.12M |
| 投资及预付款 | – | – | – | – | $20.27M |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| 经营活动现金流 | $57.46M | $25.68M | $151.99M | $43.69M | $60.83M |
| 持续经营经营活动现金流净额 | $57.46M | $25.68M | $151.99M | $43.69M | $60.83M |
| 持续经营净利润 | $4.65M | $2.92M | $7.03M | $1.64M | $5.43M |
| 折旧、折耗与摊销 | $21.30M | $21.33M | $91.02M | $21.34M | $21.19M |
| 递延税款 | $3.91M | $1.73M | $6.48M | -$3.74M | $8.07M |
| 其他非现金项目 | $2.55M | -$2.27M | -$9.63M | -$3.75M | $4.57M |
| 营运资金变动 | $16.49M | -$11.57M | -$38.27M | $14.71M | -$19.25M |
| -应收款变动 | -$10.51M | -$1.57M | -$10.74M | -$8.80M | -$897,000.00 |
| -存货变动 | $5.96M | $2.49M | -$27.57M | $4.82M | -$9.51M |
| -预付资产变动 | $4.92M | -$4.54M | -$1.21M | $12.70M | $1.47M |
| -应付账款及应计费用变动 | $15.05M | -$11.24M | $1.26M | $11.07M | -$4.48M |
| -其他流动负债变动 | $1.07M | $3.29M | – | – | -$5.83M |
| 投资活动现金流净额 | $11.76M | $19.44M | $99.48M | $19.33M | $43.61M |
| 持续经营投资活动现金流净额 | $11.76M | $19.44M | $99.48M | $19.33M | $43.61M |
| 固定资产购置及出售净额 | -$1.34M | -$2.72M | -$15.33M | -$218,000.00 | -$3.87M |
| 业务购买及出售净额 | $0.00 | -$335,000.00 | -$16.70M | $0.00 | $0.00 |
| 投资购置及出售净额 | $13.10M | $22.50M | $131.52M | $19.55M | $47.48M |
| 筹资活动现金流 | -$7.65M | -$59.40M | -$369.63M | -$51.65M | -$257.48M |
| 持续经营筹资活动现金流净额 | -$7.65M | -$59.40M | -$369.63M | -$51.65M | -$257.48M |
| 债务发行及偿还净额 | -$5.00M | -$5.00M | -$216.80M | -$5.00M | -$205.24M |
| 普通股发行净额 | $0.00 | -$50.05M | -$148.33M | -$48.25M | -$50.04M |
| 股票期权行使所得 | $843,000.00 | $2,000.00 | $3.30M | $1.72M | $12,000.00 |
| 其他筹资费用净额 | -$3.49M | -$4.36M | -$7.80M | -$126,000.00 | -$2.21M |
| 期末现金余额 | $205.88M | $144.31M | $158.55M | $158.55M | $147.59M |
| 现金净变动 | $61.57M | -$14.28M | -$118.15M | $11.37M | -$153.03M |
| 期初现金余额 | $144.31M | $158.55M | $276.77M | $147.59M | $300.48M |
| 汇率变动影响 | $0.00 | $38,000.00 | -$77,000.00 | -$414,000.00 | $133,000.00 |
| 自由现金流 | $56.12M | $22.96M | $136.66M | $43.47M | $56.96M |
| 持续经营损益 | – | – | $983,000.00 | $0.00 | – |
暂无评论——快来第一个聊聊 PCRX。
登录后参与讨论。